Table 3.

Simulations results for the idelalisib example: percent of recommendations of each dose level (D1 to D5), estimated over 10000 simulated trials, with a 4-week or 16-week observation window for toxicity, a total sample size of 60 patients, an accrual rate of 2 patients per month.

Hazard		D1	D2	D3	D4	D5	Duration
16-week obs. window (8 patients per obs.window)
Constant	True Probability of Toxicity	0.10	0.25	0.45	0.60	0.75
	% recommended by TITE-CRM	10	82	8	0	0	136 weeks
	% recommended by TITE-BOIN	12	82	6	0	0	161 weeks
4 week obs. window (2 patients per obs.window)
Decreasing	True Probability of Toxicity	0.077	0.196	0.364	0.501	0.650
	% recommended by TITE-CRM	1	65	34	0	0	122 weeks
	% recommended by TITE-BOIN	3	69	27	0	0	131 weeks
Decreasing	True Probability of Toxicity	0.056	0.147	0.281	0.396	0.534
	% recommended by TITE-CRM	0	24	68	8	0	122 weeks
	% recommended by TITE-BOIN	0	32	60	8	0	131 weeks
Constant	True Probability of Toxicity	0.026	0.069	0.139	0.205	0.293
	% recommended by TITE-CRM	0	0	7	47	45	122 weeks
	% recommended by TITE-BOIN	0	1	12	44	43	131 weeks